Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
A technology of immunoglobulin and chemokines, applied in the composition of cancer cell motility or cancer cell survival, regulating inflammation, inflammatory cell motility, and can solve non-healing wounds, chronic problems, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0183] Example 1: Production of plasmid expression vectors
[0184] pFUSE-hIgG1-Fc1, pFUSE-hIgG2-Fc1, pFUSE-hIgG3-Fc1, and pFUSE-hIgG4-Fc1 vectors from InvivoGen (San Diego, CA) were generated using standard molecular biology methods capable of expressing chemokine-immunoglobulin fusions. Polypeptide expression vector. Examples of such expression vectors are shown in Figures 1-10.
Embodiment 2
[0185] Example 2: Expression of Chemokine Receptors in Breast Cancer Cell Lines
[0186] In non-neoplastic breast tissues, experiments were performed in various stages of breast cancer tissues to compare the expression levels of CXCR7 and CXCR3. Non-neoplastic breast tissue did not express detectable levels of CXCR7. CXCR7 expression was significantly higher in advanced breast cancer tissues compared with non-neoplastic breast tissues. CXCR7 and CXCR3 mRNA were also elevated in breast cancer cell line (MDA-MB-231 ) compared to normal breast cells (MCF-10A).
Embodiment 3
[0187] Example 3: var-CXCL11-IgG fusion polypeptide inhibits CXCR7 and CXCR3 activation in breast cancer cells
[0188] Using Amnis ImageStream analysis, we found that CXCL11 stimulates the aggregation and rapid desensitization of CXCR3 and CXCR7, CXCL12 regulates modest CXCR7 clustering, and adrenomedullin (AM) stimulates CXCR3 and CXCR7 clustering. CXCL11-IgG fusion polypeptides abolish CXCR3 and CXCR7, but not CXCR4, cluster and desensitize by CXCL11, CXCL12 and AM.
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


